2135696-72-7

Basic information

• Product Name: (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide
• CAS NO: 2135696-72-7
• Molecular Weight: 461.749
• Mol File: 2135696-72-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide(2135696-72-7)
• EPA Substance Registry System: (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide(2135696-72-7)

Safety Data

• Hazardous Substances Data: 2135696-72-7(Hazardous Substances Data)

Usage

Description

(E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide is a complex organic compound featuring a pyrido[3,4-d]pyrimidin-6-yl group connected to a (3-bromo-4-chlorophenyl)amino group, with an additional 4-(dimethylamino)but-2-enamide side chain. (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide is distinguished by its unique structure, which includes a pyrido[3,4-d]pyrimidine ring, an amide group, and a substituted phenyl group. The presence of both amide and amino groups suggests potential for interaction with biological systems, hinting at possible pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
(E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide is used as a potential pharmaceutical agent for its structural features and the presence of both an amide and amino groups, which may allow for various interactions with biological systems. (E)-N-(4-((3-bromo-4-chlorophenyl)amino)pyrido[3,4-d]pyrimidin-6-yl)-4-(dimethylamino)but-2-enamide's specific application within the pharmaceutical industry would require further research and testing to determine its efficacy and safety.

Upstream product

• 52334-92-6 2-(N,N-dimethylamino)ethoxide 
• 38711-20-5 1,1-dimethoxymethyl-N,N-dimethylmethanamine 
• 171178-42-0 5-[N-(tert-Butoxycarbonyl)-amino]-2-fluoropyridine-4-carboxylic acid 
• 1827-27-6 2-fluoro-5-aminopyridine 
• 171178-41-9 (6-fluoro-pyridin-3-yl)-carbamic acid, tert-butyl ester 
• 175357-98-9 4-chloro-6-fluoro-pyrido[3,4-d]pyrimidine 
• 171178-44-2 6-fluoro-4-oxo-3H-pyrido[3,4-d]pyrimidine 
• 171178-43-1 5-Amino-2-fluoropyridine-4-carboxylic acid 

Relevant articles and documents

USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS

Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti- HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti -HER2/HER3 antibodies.